Advisory Services Network’s Amylyx Pharmaceuticals AMLX Stock Holding History

Advisory Services Network’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-500	Closed	-$14.7K	–	1512
2023 Q1	$14.7K	Hold	500	–	–	﹤0.01%	2710
2022 Q4	$18.5K	Buy	+500	New	+$17.7K	﹤0.01%	2535

Other funds holding AMLX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Advisory Services Network's AMLX Position: Q2 2023 in Review

Advisory Services Network sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2023, closing a stake of 500 shares — an estimated $14.7K sold.

Advisory Services Network first reported a position in AMLX in Q4 2022 and held it in 2 quarters. The position peaked at $18.5K in Q4 2022. 154 funds tracked by Wall St. Rank hold AMLX as of Q2 2023.

Advisory Services Network reported no remaining Amylyx Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Advisory Services Network sold 500 Amylyx Pharmaceuticals shares in Q2 2023, an estimated $14.7K.
Advisory Services Network first reported a position in Amylyx Pharmaceuticals in Q4 2022 and held it in 2 quarters.
Advisory Services Network's Amylyx Pharmaceuticals position peaked at $18.5K in Q4 2022.
154 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2023.

Based on Advisory Services Network's 13F filing for Q2 2023, filed 9 Aug 2023.